View in EDS HTML Full Text PDF Full Text

Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply.

Saved in:
Bibliographic Details
Title: Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply.
Authors: Visuri I; Örebro, Sweden., Eriksson C; Örebro, Sweden.; Stockholm, Sweden., Olén O; Stockholm, Sweden., Cao Y; Örebro, Sweden., Mårdberg E; Örebro, Sweden., Grip O; Malmö, Sweden., Gustavsson A; Karlstad, Sweden., Hjortswang H; Linköping, Sweden., Karling P; Umeå, Sweden., Montgomery S; Örebro, Sweden.; Stockholm, Sweden., Myrelid P; Linköping, Sweden., Ludvigsson JF; Örebro, Sweden.; Stockholm, Sweden., Halfvarson J; Örebro, Sweden.
Source: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Sep; Vol. 54 (6), pp. 848-849.
Publication Type: Editorial; Comment
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34425010
AccessLevel: 2
PubType: Editorial & Opinion
PubTypeId: editorialOpinion
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Visuri+I%22">Visuri I</searchLink>; Örebro, Sweden.<br /><searchLink fieldCode="AU" term="%22Eriksson+C%22">Eriksson C</searchLink>; Örebro, Sweden.; Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Olén+O%22">Olén O</searchLink>; Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Cao+Y%22">Cao Y</searchLink>; Örebro, Sweden.<br /><searchLink fieldCode="AU" term="%22Mårdberg+E%22">Mårdberg E</searchLink>; Örebro, Sweden.<br /><searchLink fieldCode="AU" term="%22Grip+O%22">Grip O</searchLink>; Malmö, Sweden.<br /><searchLink fieldCode="AU" term="%22Gustavsson+A%22">Gustavsson A</searchLink>; Karlstad, Sweden.<br /><searchLink fieldCode="AU" term="%22Hjortswang+H%22">Hjortswang H</searchLink>; Linköping, Sweden.<br /><searchLink fieldCode="AU" term="%22Karling+P%22">Karling P</searchLink>; Umeå, Sweden.<br /><searchLink fieldCode="AU" term="%22Montgomery+S%22">Montgomery S</searchLink>; Örebro, Sweden.; Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Myrelid+P%22">Myrelid P</searchLink>; Linköping, Sweden.<br /><searchLink fieldCode="AU" term="%22Ludvigsson+JF%22">Ludvigsson JF</searchLink>; Örebro, Sweden.; Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Halfvarson+J%22">Halfvarson J</searchLink>; Örebro, Sweden.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228707234%22">Alimentary pharmacology & therapeutics</searchLink> [Aliment Pharmacol Ther] 2021 Sep; Vol. 54 (6), pp. 848-849.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Editorial; Comment
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>8707234 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1365-2036 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2202692813%22">02692813 </searchLink><i>NLM ISO Abbreviation: </i>Aliment Pharmacol Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34425010
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/apt.16569
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 848
    Titles:
      – TitleFull: Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Visuri I
      – PersonEntity:
          Name:
            NameFull: Eriksson C
      – PersonEntity:
          Name:
            NameFull: Olén O
      – PersonEntity:
          Name:
            NameFull: Cao Y
      – PersonEntity:
          Name:
            NameFull: Mårdberg E
      – PersonEntity:
          Name:
            NameFull: Grip O
      – PersonEntity:
          Name:
            NameFull: Gustavsson A
      – PersonEntity:
          Name:
            NameFull: Hjortswang H
      – PersonEntity:
          Name:
            NameFull: Karling P
      – PersonEntity:
          Name:
            NameFull: Montgomery S
      – PersonEntity:
          Name:
            NameFull: Myrelid P
      – PersonEntity:
          Name:
            NameFull: Ludvigsson JF
      – PersonEntity:
          Name:
            NameFull: Halfvarson J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2021 Sep
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1365-2036
          Numbering:
            – Type: volume
              Value: 54
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Alimentary pharmacology & therapeutics
              Type: main
ResultId 1